Poster #2: A dual 6-month & 18-month prospective, randomized, placebo-controlled, double-blind, pivotal clinical trial investigating efficacy and safety of buntanetap in early Alzheimer's patients.

Poster #4: Pharmacokinetic characterization of buntanetap in plasma of patients with early Alzheimer’s and Parkinson’s diseases. Presenter: Matthew Peterson, Ph.D., Senior Clinical Scientist. The AAIC ...

Aquestive Therapeutics to present Anaphylm™ (epinephrine) Sublingual Film results at CFAAR Summit, potentially the first oral epinephrine treatment.

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin ...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...